V
323990
vs
K
KOSPI 200
Over the past 12 months, Vaxcell Bio Therapeutics has underperformed KOSPI 200, delivering a return of -1% compared to the KOSPI 200's +121% growth.
Stocks Performance
323990 vs KOSPI 200
Performance Gap
323990 vs KOSPI 200
Performance By Year
323990 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vaxcell Bio Therapeutics
Glance View
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.
